A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.
The press release outlines that this study has met its primary endpoint of PFS at final analysis as well as secondary endpoints of OS at interim analysis and ORR.
